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OBJECTIVES The goal of this study was to assess the prognostic role of the Lewis antigenic system,
Chlamydia pneumoniae (CP) seropositivity (CP), and C-reactive protein (CRP) levels in
unstable angina (UA).
BACKGROUND The role of CP infection in acute coronary syndromes is contradictory. The Lewis antigenic
system, a genetically determined blood group system associated with infections and several
disorders, including ischemic heart disease, might influence the susceptibility to CP infection,
inflammatory response, and risk of cardiac ischemic events.
METHODS The CRP levels, Lewis antigens, and CP were measured in 54 patients with Braunwald’s
class IIIB UA. All patients were followed up for one year, and the occurrence of new coronary
events (coronary death, myocardial infarction, and recurrence of instability) were recorded.
RESULTS Twenty-five coronary events occurred during follow-up. At univariate analysis CRP 3 mg/l
(CRP) (p  0.0056), Lewis antigen b (Leb) (p  0.028), and the combination of Leb
and CP (p  0.006) and of CRP and Leb (p  0.003) were associated with new
coronary events, while CP alone was not. At multivariate analysis, CRP (p  0.008) and
combined LebCP (p  0.03) were independent predictors of worse outcome. The event
rate was 64% in CRP patients, 67% in LebCP patients, and 86% in CRPLebCP
patients. Combined LebCP, but not Leb and CP alone, was related to CRP levels
(p  0.03). Among CP patients, CRP levels were higher in Leb than Leb- (p  0.028).
CONCLUSIONS Our data demonstrate that in UA the Lewis antigenic system plays an important role,
probably determining individual susceptibility to the detrimental effects of CP infection and
by determining an enhanced inflammatory response. (J Am Coll Cardiol 2003;41:546–50)
© 2003 by the American College of Cardiology Foundation
In the majority of patients with unstable angina (UA),
systemic signs of inflammation are detectable (1,2). Such an
inflammatory component has a short- and long-term prog-
nostic value in patients with UA and in normal subjects
(3–6). However, the cause of such inflammatory response is
unclear. Recently, the possibility that some infectious agents
may contribute to atherogenesis has been raised. In partic-
ular, Chlamydia pneumoniae (CP) has been associated with
ischemic heart disease (IHD) (7,8). However, data in
literature are contradictory, and the evidence for such
association is not conclusive (9,10), possibly because of an
uneven sensitivity to this pathogen. The high prevalence of
CP infection in the adult population suggests the possibility
that the individual host response may be crucial and that CP
may have a role only in patients having a specific genetic
susceptibility.
In this setting a possible role may be played by the Lewis
antigenic system. This genetically determined blood group
system is composed of two antigens, Lewis a (Lea) and
Lewis b (Leb), whose expression is determined by two
fucosyltrasferase genes located on chromosome 19. Accord-
ing to an individual’s genotype and, therefore, to the
expression of either one or of both putative genes, three
phenotypes (Lea, Leb, Lea-b-) are observed in the
Caucasian population (11). A rare Lewis phenotype,
Leab, has also been described in some Asian ethnic
groups, but it is generally not observed in our population
(12). The Lewis antigens are localized on cell surfaces and in
organic liquids and are known to be associated with a variety
of infectious diseases, including pulmonary infections and
Helicobacter pylori (HP) infection (13,14); it is hypothesized
that these antigens may act through an adhesive mechanism
(15). Furthermore, the Lewis antigenic system has been
associated with several clinical disorders associated with
IHD such as elevated levels of factor VIII and von Wille-
brand factor, metabolic syndrome X, insulin resistance, and
dyslipidemia (16–18). The Lewis antigenic system has also
been recognized as a genetic marker of IHD (19,20), and
polymorphisms of a fucosyltrasferase gene involved in Lewis
antigen expression have been suggested to be associated
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with atherosclerotic disease and inflammatory response (21).
In particular, because the Leb antigen has been associated
with infectious disease, such as HP infection (14), which
has also been associated with IHD, and with pulmonary
infections (13), we studied the relation of this antigen with
C-reactive protein (CRP) levels, CP seropositivity, and
prognosis in UA.
METHODS
Population. We studied 54 consecutive patients with
Braunwald’s class IIIB UA (42 men; mean age, 61  9
years) admitted to our coronary care unit. Inclusion criteria
on admission were angina at rest, with 2 ischemic epi-
sodes or 1 episode lasting 20 min in the last 24 h with
diagnostic ST-segment shift and negative creatine
kinase-MB and troponin T, in order to avoid any confound-
ing effect of myocardial damage on the inflammatory
response. Patients were excluded if they had any known
condition associated with inflammatory response and con-
ditions likely to be associated with reduced survival, includ-
ing ejection fraction 40% and age over 75 years (3). All
patients were followed up for one year, during which the
occurrence of new coronary events defined as coronary
death, myocardial infarction, and recurrence of instability,
with documented electrocardiogram changes, requiring re-
admission to hospital, were recorded.
The study was approved by the Ethics Committee of the
Catholic University, and all patients gave their informed
consent.
Blood and laboratory assays. All patients were bled at
hospital admission. The CRP plasma levels were measured
using a high-sensitivity nephelometric system (BNII, Dade-
Behring, Marburg, Germany). The CP antibody titers
were measured by a microimmunofluorescence assay (MRL
Diagnostics MIF kit, Santa Barbara, California). Samples
were diluted from 1:8 to 1:64; CP seropositivity was defined
as the presence of specific immunoglobulin (Ig)G antibodies
1:16. Lewis antigens (Lea, Leb) were determined by a
direct hemoagglutination method (Seraclone anti-Lea, anti-
Leb, Biotest AG, Dreieich, Germany).
Statistical analysis. Because CRP values were not nor-
mally distributed, data are presented as median and range.
Nonparametric tests were used for comparisons of CRP
levels between groups (Mann-Whitney U test). Chi-square
analysis was used for noncontinuous variables using Yates
correction. Univariate and multivariate logistic regression
analysis, after log transformation of CRP values, were
carried out to assess the determinants of outcome, and
multiple regression analysis was used to assess the parame-
ters associated with CRP levels. As confounders, we ana-
lyzed CRP 3 mg/l (CRP), positivity towards CP and
Leb, combination of these three confounders (LebCP,
LebCRP, CPCRP, LebCPCRP), gender,
age, hypertension (defined as systolic blood pressure 140
mm Hg and diastolic blood pressure 90 mm Hg, or the
need for antihypertensive medication), presence of diabetes
mellitus (defined as fasting glucose levels 140 mg/dl,
including both insulin-dependent and noninsulin-
dependent diabetes mellitus), hypercholesterolemia (defined
as total cholesterol 200 mg/dl or the need for lipid-
lowering therapy), family history of IHD (defined as history
of IHD in siblings, parents, or first cousins 65 years of
age), severity of coronary disease (according to number of
diseased vessels with a diameter stenosis 70% assessed by
quantitative coronary angiography), and smoking habits
(current smokers or former smokers within the previous
month). Only parameters with a trend toward significance
(p  0.1) were included in the multiple regression analysis;
however, as inclusion of CRP, Leb, CRPLeb,
CPLeb, and CRPLebCP led to colinearity, only
CRP and the association of LebCP were included for
multivariate analysis as they did not lead to colinearity. All
other associations (CRPCP, CRPLeb, CRP
LebCP), in fact, contained at least one of the other
confounders, implicating that they were not independent.
RESULTS
Demographic and clinical characteristics of patients accord-
ing to the presence or absence of the Leb antigen are
summarized in Table 1. As only four patients were Leb-CP-
(one of whom developed a cardiovascular event), this group
was not included for subgroup analysis. During one-year
follow-up, 25 new coronary events were observed. In the
overall population, CRP median levels were 4.5 mg/l (0.5 to
188 mg/l); 21/33 (64%) patients with CRP 3 mg/l versus
4/21 (19%) patients with CRP 3 mg/l had new coronary
events (p  0.0035). Median CRP levels were 7.3 mg/l
(0.7 to 188 mg/l) in patients with new coronary events and
2.9 mg/l (0.5 to 32.9 mg/l) in those without events (p 
0.015); 37/54 (68.5%) patients were Leb, and 34/54
(63%) patients were CP at hospital admission. The Leb
antigen expression, but not CP seropositivity, was associated
with new coronary events after one year (p  0.048) (Table
2). No difference was observed in CP IgG titers between
Abbreviations and Acronyms
ACS  acute coronary syndromes
CABG  coronary artery bypass grafting
CI  confidence interval
CP  Chlamydia pneumoniae
CRP  C-reactive protein
HP  Helicobacter pylori
IgG  immunoglobulin G
IHD  ischemic heart disease
Lea  Lewis a antigen
Leb  Lewis b antigen
OR  odds ratio
UA  unstable angina
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patients with and without events. Combined positivity for
CRP 3 mg/l and Leb increased the event rate to 72%.
New coronary events were significantly associated with
the combined positivity toward Leb and CP, as they were
observed in 67% of LebCP patients, versus 44%
LebCP- and 23% Leb-CP patients (p  0.043). The
highest incidence of new events was observed in patients
with combined positivity for CRP 3 mg/l, Leb, and CP
(86%) (Table 3).
In a logistic regression analysis, CRP 3 mg/l (p 
0.0056), Leb antigen expression (p  0.028), but not CP
seropositivity per se (p  0.48), were associated with
outcome. Only CRP 3 mg/l (p  0.008; odds ratio [OR],
5.74; confidence interval [CI], 1.5 to 21.7) and LebCP
(p  0.03; OR, 4.1; CI, 1.4 to 14.9) were independently
associated with outcome (Table 4). In a multiple regression
analysis, CRP levels were not related to CP seropositivity,
Leb antigen expression, or any of the other confounders
analyzed, but to the combination of CP seropositivity and
Leb antigen expression (p  0.03). Among CP patients,
CRP levels were higher in Leb (median, 6.5 mg/l; range,
0.85 to 188 mg/l) than Leb- (median, 2.88 mg/l; range, 0.5
to 14.9 mg/l) patients (p  0.028). The CP seropositivity
was not associated with any Lewis antigen.
In the overall study population, 53/54 patients performed
coronary angiography. Coronary revascularization was per-
formed in 49/54 patients (20 percutaneous transluminal
coronary angioplasty and 29 coronary artery bypass grafting
[CABG] interventions). Percutaneous transluminal coro-
nary angioplasty was performed in 16 patients and CABG
in 19 patients in the Leb group. Percutaneous translumi-
nal coronary angioplasty was performed in 4 patients and
CABG in 10 patients in the Leb- group (p  0.27).
DISCUSSION
Our study demonstrates that the Leb antigen is associated
with new coronary events in a carefully selected homoge-
Table 1. Demographic and Clinical Characteristics of the
Study Population
Leb Leb
Number of patients (%) 37/54 (68.5) 17/54 (31.5)
Age, yrs, mean  SD 61  10 62  8
Gender (M/F) 27/10 15/2
Risk factors
Family history of IHD (%) 19 (51) 5 (29)
Hypercholesterolemia (%) 16 (43) 7 (41)
Diabetes (%) 9 (24) 3 (18)
Hypertension (%) 21 (57) 9 (53)
Smoking (%) 20 (54) 8 (47)
Medications
Nitrates (%) 23 (62) 11 (65)
Beta-blockers (%) 23 (62) 9 (53)
Calcium blockers (%) 21 (57) 10 (59)
Aspirin (%) 33 (89) 16 (94)
Other antiplatelet agents (%) 4 (11) 1 (6)
Lipid-lowering agents (%) 17 (46) 6 (35)
ACE inhibitors (%) 7 (19) 3 (17)
CRP  3 mg/l (%) 25 (67.5) 10 (59)
IgG-CP (1:16) (%) 21 (57) 13 (76)
All p were NS.
ACE  angiotensin-converting enzyme; CP  Chlamydia pneumoniae; CRP 
C-reactive protein; IHD  ischemic heart disease; Leb  Lewis antigen b.
Table 2. Event Rate in the Study Population
Total Events UA MI D
CRP  3 mg/l 21/33 (64%) 19/33 2/33 0
CRP  3 mg/l 4/21 (19%) 4/21 0 0
P 0.0035 0.0121 NS NS
Leb 21/37 (56.8%) 19/37 2/37 0
Leb 4/17 (23.5%) 4/17 0 0
p Value 0.048 NS NS NS
CP 17/34 (50%) 15/34 2/34 0
CP 8/20 (40%) 8/20 0 0
p Value NS NS NS NS
D  coronary death; MI  myocardial infarction; UA  recurrence of instability
requiring readmission to hospital. Other abbreviations as in Table 1.
Table 3. Event Rate for Combined Factors
Total
Events UA MI D
LebCP 14/21 (67%) 12/21 2/21 0
Non-LebCP 11/33 (33%) 11/33 0 0
p Value 0.048 NS NS NS
LebCRP  3 mg/l 18/25 (72%) 16/25 2/25 0
Non-LebCRP  3 mg/l 7/29 (24%) 7/29 0 0
p Value 0.028 NS NS NS
CPCRP  3 mg/l 14/18 (78%) 12/18 2/18 0
Non-CPCRP  3 mg/l 11/36 (30%) 11/36 0 0
p Value 0.007 NS NS NS
LebCPCRP  3 mg/l 12/14 (86%) 10/14 2/14 0
Non-LebCPCRP  3 mg/l 13/40 (32%) 13/40 0 0
p Value 0.004 0.015 NS NS
Chi-square analysis with Yates correction.
Abbreviations as in Tables 1 and 2.
Table 4. Univariate and Multivariate Logistic Analysis of
Outcome Determinants
p Value OR (95% CI)
Univariate logistic analysis
CRP  3 mg/l 0.0056 5.67 (1.6–19.9)
Leb 0.028 4.26 (1.13–16)
CP 0.48 1.5 (0.47–4.7)
CPLeb 0.006 5.5 (1.5–19)
CPCRP 0.001 9.02 (2.2–36)
CRPLeb 0.003 6.25 (1.8–21.5)
CPCRPLeb 0.0002 8.67 (2–38.6)
Severity of coronary disease 0.82 1.2 (0.56–2.06)
Family history of IHD 0.88 0.92 (0.29–2.86)
Diabetes 0.79 1.2 (0.29–4.9)
Hypercholesterolemia 0.67 1.26 (0.40–3.9)
Smoking habits 0.33 1.75 (0.54–5.6)
Age 0.83 0.99 (0.93–1.05)
Gender 0.10 0.3 (0.06–1.3)
Hypertension 0.54 1.4 (0.46–4.4)
Revascularization 0.89 0.9 (0.7–1.3)
Multivariate logistic analysis
CRP  3 mg/l 0.008 5.74 (1.5–21.7)
CPLeb 0.03 4.1 (1.4–14.9)
CI  confidence interval; OR  odds ratio. Other abbreviations as in Table 1.
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neous group of patients with severe UA Braunwald’s class
IIIB and that such a relation is strengthened when associ-
ated with raised levels of CRP and CP seropositivity.
Conversely, CP seropositivity is associated with new coro-
nary events only when combined with Leb and CRP 
3 mg/l. Patients CP, Leb having CRP  3 mg/l have
the greatest risk. Therefore, our data suggest that the
inflammatory response is a major determinant of the asso-
ciation between infections and acute coronary syndromes
(ACS).
Role of the Lewis antigenic system. The mechanisms by
which the Lewis antigens may be involved in IHD and their
interaction with CP and inflammation are speculative. First,
the Lewis genes are located on chromosome 19, nearby the
loci of the low-density lipoprotein receptor, the glycogen
synthetase, and the insulin receptor, suggesting a possible
interaction between these genes and development of IHD
(19). Second, the Lewis antigens are also soluble in plasma
(11), where they may interact with circulating CP antigens
and eventually favor plaque localization. According to such
hypothesis, plaque localization of CP antigens and the
development of IHD may be secondary to the release of CP
antigens into plasma from an extracardiac localization (22–
24). Third, a polymorphism of the Lewis genes (11)
determines a quantitative difference in antigen expression,
which might explain a different susceptibility towards CP
infection and/or a different inflammatory response. There-
fore, the previous evidence of the Lewis antigenic system as
a genetic marker of IHD (19,20) may have both a biological
and molecular explanation. In fact, the abovementioned
pathogenic mechanisms, although speculative, are based on
previous studies (11,21–24) concerning this antigenic sys-
tem although not directly applied to IHD. The genetic
background of this blood group system and the presence of
polymorphisms regulating antigen expression, along with
the modulating properties towards several microorganisms,
suggest that the Lewis antigens may play a role in the
multifactorial (endogenous and environmental components)
pathophysiology of IHD.
Previous studies. Previous studies, mainly retrospective,
have suggested an association between CP infection and
IHD (8,25–27); this hypothesis has also generated a number
of prospective studies on the role of specific antibiotic
treatment in IHD patients (28–31). However, more recent
prospective data have failed to confirm such an association
(9,10,32,33), and a meta-analysis published by Danesh et al.
(33) excluded the existence of any strong association be-
tween CP IgG titers and incident coronary artery disease.
Conversely, studies assessing the association of CP or other
infective agents with markers of inflammation have sug-
gested a strong association between infections and risk of
IHD in the presence of elevated inflammatory markers
(34,35). Such an observation, and our finding that CRP
levels are associated with the combined positivity toward CP
and Leb, suggests that the role of infectious agents in
atherogenesis and its complications may be, in part, related
to the amount of inflammatory response to infections,
which, in turn, may depend on a host’s genetic background
(36,37).
Role of the host response. Seropositivity towards CP
infection is quite frequent in the adult population, but very
few of these individuals develop ACS. This suggests that
CP infection alone is not able to determine the development
of ACS, but other factors are required. In particular, in our
study we analyzed a small, but well characterized, group of
patients with severe UA. In UA, the inflammatory process
plays an important pathogenic role, and inflammatory
markers are related to prognosis. Our findings confirm CRP
as a major prognostic determinant but also demonstrate that
patients with combined CP seropositivity and Leb antigen
expression are characterized by a greater inflammatory
response and a greater risk of future coronary events. Our
findings suggest an important role of the host response in
the association between infections and ACS and contribute
to explaining the controversial results on the role of infec-
tious agents in the pathogenesis of ACS and on the
beneficial effects of antibiotics in patients with ACS.
Although this study included a small number of patients
(which might, in part, explain the lack of correlation of the
traditional risk factors with prognosis) and lack of measure-
ment of specific CP antigens (38), it suggests, in line with
recent observations (35), that the association between CP
and UA may be mediated by inflammation and by the host’s
genetic background.
Conclusions. Our study demonstrates that patients with
UA carrying the Leb antigen have a worse outcome at 12
months; among these, those who are seropositive to CP and
have elevated CRP levels have the highest risk of new
coronary events. Thus, the Lewis antigenic system might
have a pathogenic role in the susceptibility to infectious
agents in UA and influence patients’ outcome. The CP
infection may not produce adverse coronary events in
nonresponsive patients. Further studies are needed to con-
firm the role of the Lewis antigens in the development of
ACS and to clarify their interaction with infectious agents
and inflammation.
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